Mundipharma signs a deal with Grü­nen­thal

BioSpectrum (Asia) - - Company News -

Mundipharma has en­tered into a li­cense and dis­tri­bu­tion agree­ment with the sci­ence­based phar­ma­ceu­ti­cal com­pany Grü­nen­thal, spe­cial­ized in pain, gout and in­flam­ma­tion. As per the agree­ment, Mundipharma will mar­ket and dis­trib­ute Grü­nen­thal’s Tra­mal (tra­madol) in China from May 1, 2018.

Tra­mal is a well-es­tab­lished anal­gesic for the treat­ment of mod­er­ate to se­vere pain. It is the only in­ter­na­tional brand of tra­madol in China that in­cludes sus­tained re­lease tablets and im­me­di­ate re­lease cap­sules, as well as an in­tra­venous for­mu­la­tion used for post-op­er­a­tive pain in pa­tient con­trolled in­tra­venous anal­ge­sia (PCIA). De­liv­er­ing the anal­gesic in­tra­venously with a pa­tient-con­trolled de­vice can pro­vide an im­por­tant and ef­fec­tive pain con­trol op­tion for pa­tients.

Both or­gan­i­sa­tions are com­mit­ted to en­sur­ing the re­spon­si­ble use of anal­gesic med­i­ca­tions to treat post­op­er­a­tive pa­tients when other op­tions pro­vide in­suf­fi­cient re­lief. The Grü­nen­thal Group in­tends to de­liver four to five new prod­ucts to pa­tients in dis­eases with high un­met med­i­cal need by 2022 and be­come a €2 bil­lion com­pany.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.